Polysaccharide peptides from COV-1 strain of Coriolus versicolor inhibit tolbutamide 4-hydroxylation in the rat in vitro and in vivo

Food and Chemical Toxicology

Volumn 44, Issue 8, 2006, Pages 1414-1423

  Yeung, John H K ^a   Chan, Siu Lung ^a   Or, Penelope M Y ^a  

^a and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

Author keywords

4 Hydroxytolbutamide; Coriolus versicolor; Polysaccharide peptide (PSP); Tolbutamide metabolism

Indexed keywords

4 HYDROXYTOLBUTAMIDE; CYTOCHROME P450; CYTOCHROME P450 2C; CYTOCHROME P450 2C9; OXYGENASE; PEPTIDE; POLYSACCHARIDE; POLYSACCHARIDE PEPTIDE; SULFAPHENAZOLE; TOLBUTAMIDE; TOLBUTAMIDE 4 HYDROXYLASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CORIOLUS VERSICOLOR; DRUG CLEARANCE; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME KINETICS; FUNGAL STRAIN; FUNGUS; HYDROXYLATION; IC 50; IN VITRO STUDY; IN VIVO STUDY; LIVER MICROSOME; MALE; NONHUMAN; RAT;

ANIMALS; BASIDIOMYCOTA; CARBOHYDRATE SEQUENCE; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; HYDROXYLATION; HYPOGLYCEMIC AGENTS; ISOENZYMES; LIVER; MALE; MICROSOMES, LIVER; MOLECULAR SEQUENCE DATA; PROTEOGLYCANS; RATS; RATS, SPRAGUE-DAWLEY; SULFAPHENAZOLE; TOLBUTAMIDE;

TRAMETES VERSICOLOR;

EID: 33745210539     PISSN: 02786915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fct.2006.03.007     Document Type: Article

References (32)

1. Chan S.L., and Yeung J.H.K. Effects of polysaccharide peptide (PSP) from C. versicolor on the pharmacokinetics of cyclophosphamide in the rat and cytotoxicity in HepG2 cells. Food Chem. Toxicol. 44 (2006) 689-694
2. Chan, S.L., Yeung, J.H.K., 2006b. Modulation of antipyrine clearance by polysaccharide peptide isolated from C. versicolor in the rat Food Chem. Toxicol., in press, doi:10.1016/j.fct.2006.03.008.
3. Chang T.K., Weber G.F., Crespi C.L., and Waxman D.J. Differential activation of cyclophosphamide and ifosphamide by cytochromes P450 2B and 3A in human liver microsomes. Cancer Res. 53 (1993) 5629-5637
4. Eagling V.A., Tjia J.F., and Back D.J. Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes. Br. J. Clin. Pharmacol. 45 2 (1998) 107-114
5. Easterbrook J., Fackett D., and Li A.P. A comparison of aroclor 1254-induced and uninduced rat liver microsomes to human liver microsomes in phenytoin O-deethylation, coumarin 7-hydroxylation, tolbutamide 4-hydroxylation, S-mephenytoin 4′-hydroxylation, chloroxazone 6-hydroxylation and testosterone 6β-hydroxylation. Chem. Biol. Interact. 134 (2001) 243-249
6. Foster B.C., Arnason J.T., and Briggs C.J. Natural health products and drug disposition. Annu. Rev. Pharmacol. Toxicol. 45 (2005) 203-226
7. Go P., and Chung C.H. Adjuvant PSK immunotherapy in patients with carcinoma of the nasopharynx. J. Int. Med. Res. 17 (1989) 141-149
8. Hayakawa K., Mitsuhashi N., Saito Y., Takahashi M., Katano S., Shiojima K., Furuta M., and Niibe H. Effect of krestin (PSK) as adjuvant treatment on the prognosis after radical radiotherapy in patients with non-small cell lung cancer. Anticancer Res. 13 (1993) 1815-1820
9. Hu Z., Yang X., Ho P.C.L., Chan S.Y., Heng P.W.S., Chan E., Duan W., Koh H.L., and Zhou S. Herb-drug interactions: a literature review. Drugs 65 9 (2005) 1239-1282
10. Kidd P.M. The use of mushroom glucans and proteoglycans in cancer treatment. Altern. Med. Rev. 5 (2000) 4-27
11. Kirchheiner J., and Brockmoller J. Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin. Pharmacol. Ther. 77 (2005) 1-16
12. Kodama Y., Kano T., Tamada R., Kumashiro R., Okamura T., and Inokuchi K. Combined effect of prophylactic lymphadenectomy and long term combination chemotherapy for curatively resected carcinoma of the stomach. Jpn. J. Surg. 12 (1982) 244-248
13. Liu J.X., Zhou J.Y., and Liu T.F. Phase III clinical trial for the Yun Zhi polysacchride (PSP) capsules. In: Yang Q.Y. (Ed). Advanced Research in PSP 1999 (1999), The Hong Kong Association for Health Care Limited, Hong Kong 295-303
14. Lowry O.H., Rosebrough N.J., Farr A.L., and Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 243 (1951) 1331-1332
15. Mitomi T., Tsuchiya S., Iijima N., Aso K., Suzuki K., Nishiyama K., Amano T., Takahashi T., Murayama N., Oka H., et al. Randomized, controlled study on adjuvant immunochemotherapy with PSK in curatively resected colorectal cancer. The Cooperative Study Group of Surgical Adjuvant Immunochemotherapy for Cancer of Colon and Rectum (Kanagawa). Dis. Colon. Rectum. 35 (1992) 123-130
16. Monro J.A. Treatment of cancer with mushroom products. Achiv. Environ. Health 58 8 (2003) 533-537
17. Ogoshi K., Satou H., Isono K., Mitomi T., Endoh M., and Sugita M. Possible predictive markers of immunotherapy in esophageal cancer: retrospective analysis of a randomized study. Cancer Invest. 13 (1995) 363-369
18. Qian Z.M., Xu M.F., and Tang P.L. Polysaccharide peptide (PSP) restores immunosuppression induced by cyclophosphamide in rats. In: Yang Q.Y. (Ed). Advanced Research in PSP 1999 (1999), The Hong Kong Association for Health Care Limited, Hong Kong 154-163
19. Rettie A.E., and Jones J.P. Clinical and toxicological relevance of CYP2C9: Drug-drug interactions and pharmacogenetics. Annu. Rev. Pharmacol. Toxicol. 45 (2005) 477-494
20. Schenkman J.B., and Jansson I. Spectral analysis of cytochrome P450. In: Phillips I.R., and Stephard E.A. (Eds). Methods in Molecular Biology. Cytochrome P450 Protocols vol. 107 (1998), Human Press Inc., Totowa 25-33
21. Sladek N.E. Therapeutic efficiency of cyclophosphamide as a function of its metabolism. Cancer Res. 32 (1972) 535-542
22. Veronese M.E., Mcmanus M.E., Laupattarakasem P., Minors J.O., and Birkett D.J. Tolbutamide hydroxylation by human, rabbit and rat liver microsomes by purified forms of cytochrome P450. Drug Metab. Dispos. 18 (1990) 356-361
23. Wang S.Y., Hsu M.L., and Yang X.T. Growth inhibition and apoptosis in human leukemia cells induced by cytokines released from PSP-activated blood mononuclear cells. In: Yang Q.Y. (Ed). Advanced Research in PSP 1999 (1999), The Hong Kong Association for Health Care Limited, Hong Kong 128-130
24. Yang Q.Y., Hu Y.J., Li X.Y., Yang J.C., Liu J.X., Liu T.F., Xu G.M., and Liao M.L. A new biological response modifier substance - PSP. In: Yang Q.Y., and Kwok C.Y. (Eds). 1993 PSP International Symposium, Anthology of Theses and Abstracts (1993), Fudan University Press, Shanghai 55-72
25. Yeung J.H.K., Chiu L.C.M., and Ooi V.E. Effect of polysaccharide peptide (PSP) on glutathione and protection against paracetamol-induced hepatotoxicity in the rat. Meth. Find Exp. Clin. Pharmacol. 16 (1994) 723-729
26. Yeung J.H.K., Chiu L.C.M., and Ooi V.E. Effect of polysaccharide peptide (PSP) on in vivo sulphation and glucuronidation of paracetamol in the rat. Eur. J. Drug Metab. Pharmacokinet. 20 (1995) 287-292
27. Yu L., and Waxman D.J. Role of cytochrome P450 in oxa-phosphorine metabolism: deactivation via N-dechloroethylation and activation via 4-hydroxylation catalyzed by distinct subsets of rat liver cytochromes P450. Drug. Metab. Dispos. 24 (1996) 1254-1262
28. Zhang L.Y., Zhong Y., and Zhou J. The observation of PSP decrease 60 cases chemotherapeutical stomach cancer's side effect. In: Yang Q.Y. (Ed). Advanced Research in PSP 1999 (1999), The Hong Kong Association for Health Care Limited, Hong Kong 328
29. Zhang J., Tian Q., Chan Y.S., Li S.C., Zhou S., Duan W., and Zhu Y.Z. Metabolism and transport of oxazaphosphorines and the clinical implications. Drug Metab. Rev. 37 4 (2005) 611-703
30. Zhou Y.L., and Yang Q.Y. Active principles from Coriolus sp. In: Yang Q.Y. (Ed). Advanced Research in PSP 1999 (1999), The Hong Kong Association for Health Care Limited, Hong Kong 111-124
31. Zhou S., Gao Y., Jiang W., Huang M., Xu A., and Paxton J.W. Interactions of herbs with Cytochrome P450. Drug Meta. Rev. 35 1 (2003) 35-98
32. Zhou S., Lim L.Y., and Chowbay B. Herbal modulation of P-glycoprotein. Drug Meta. Rev. 36 1 (2004) 57-104